Mindray Defines Future of Imaging Technologies with New General Imaging, Women’s Healthcare and Cardiology Ultrasound Solutions

SHENZHEN, China, May 31, 2021 /PRNewswire/ — Mindray (SZSE: 300760), a global leading developer and provider of medical devices and solutions, has announced the launch of its new General Imaging, Women’s Healthcare, and Cardiology ultrasound solutions on May 28, 2021. Underpinned by the theme “Innovation Defines”, each solution is specifically designed to increase the strength of […]

SHENZHEN, China, May 31, 2021 /PRNewswire/ — Mindray (SZSE: 300760), a global leading developer and provider of medical devices and solutions, has announced the launch of its new General Imaging, Women’s Healthcare, and Cardiology ultrasound solutions on May 28, 2021. Underpinned by the theme “Innovation Defines”, each solution is specifically designed to increase the strength of diagnostic evidence available to doctors to ensure better patient care.

Mindray Defines Future of Imaging Technologies with New General Imaging, Women’s Healthcare and Cardiology Ultrasound Solutions

“For over 30 years, innovation has been deeply-rooted in Mindray’s DNA. With hospital systems growing and expanding, it is imperative for the healthcare industry to continue to go beyond designing individual products to engineering connected healthcare solutions. It is with this holistic view that we can ensure an improved healthcare experience for patients, whilst helping to expand clinical capacity,” said He Xujin, General Manager of Mindray Medical Imaging Systems. “The launch of our latest ultrasound solutions marks a milestone for Mindray, as we continue to pioneer new platforms under the guiding principle, ‘Innovation Defines’”.

Mindray’s General Imaging ultrasound solutions are equipped with a number of advanced technologies, including high frame rate contrast-enhanced ultrasound (HiFR CEUS), comprehensive HiFR elastography, and enhanced quantification measurement for a new level of image clarity. These features provide clinicians with extensive tools for more precise diagnosis and treatment — giving them reinforced confidence for improved patient outcomes.

The Women’s Healthcare ultrasound solutions offer a diversified range of expert tools that includes Smart Scene 3D, Smart Planes CNS, Smart ICV, Smart Pelvic and Smart ERA. These features have been designed and inspired by the daily work of clinicians with the aim of enhancing efficiency for OBGYN applications, including IVF, neonatal and postpartum.

For cardiovascular clinicians, Mindray’s new Cardiology ultrasound solutions include TEE imaging, HiFR V-Flow, Wall Shear Stress (WSS), real time IMT. These technologies allow for truly accurate visualization, which arms clinicians with extra evidence for diagnostic certainty.

Mindray draws upon its deep insights into unmet clinical needs to provide clinicians with comprehensive imaging solutions that allow for precise diagnoses and treatments across different applications. The three latest medical imaging solutions combine extraordinary technologies with smart applications and an intuitive workflow that elevates the quality of clinical data to a higher level. At the same time, patients can benefit from faster medical imaging and more accurate detection of potential complications, all at the point of care.

Photo – https://mma.prnewswire.com/media/1516663/Innovation_defines.jpg

ST, RAMSEM open first African sorting lab

NAVASOTA, Texas, May 28, 2021 (GLOBE NEWSWIRE) — Global livestock semen sorting leader and innovator Sexing Technologies® (ST) has partnered with pioneering livestock artificial insemination company RAMSEM to establish Africa’s first semen sorting lab. The lab is at RAMSEM’s facility near Bloemfontein, South Africa. The lab will produce fresh and frozen sex-sorted semen from sheep, goats […]

NAVASOTA, Texas, May 28, 2021 (GLOBE NEWSWIRE) — Global livestock semen sorting leader and innovator Sexing Technologies® (ST) has partnered with pioneering livestock artificial insemination company RAMSEM to establish Africa’s first semen sorting lab. The lab is at RAMSEM’s facility near Bloemfontein, South Africa.

The lab will produce fresh and frozen sex-sorted semen from sheep, goats and cattle. ST’s sex sorting method separates X chromosome (female) bearing sperm from Y chromosome (male) bearing sperm through a process called flow cytometry. This provides customers with semen that is more than 90 percent accurate for the desired gender and achieves conception rates comparable to conventional (unsorted) semen used for artificial insemination.

RAMSEM is a globally renowned leader in sheep and goat reproductive services, most notably the semen freezing and laparoscopic artificial insemination (A.I.) techniques introduced to South Africa in 1985 by Dr. Johan Steyn, one of the company’s founders. Since its founding, RAMSEM has expanded its service offerings to include embryo transfer (ET) and exporting sheep genetics worldwide. Dr. Johan Steyn remains on staff as head of the company’s laparoscopic A.I. and ET programs

“Ramsem is privileged to partner with Sexing Technologies, the most reputable name in the business of semen sorting services,” says Dr. Fanie Steyn, RAMSEM Managing Director and son of Dr. Johan Steyn. “This partnership introduced semen sorting to the African continent and is set to revolutionize the breeding industry for Southern African cattle, sheep and goats. ST’s cutting edge research and development work has resulted in its flagship sorted semen product, SexedULTRA, which is already producing results comparable to conventional fresh semen laparoscopic A.I. in South Africa.

“This partnership truly embodies RAMSEM’s motto that ‘experience plus technology equals results!’” Dr. Fanie Steyn adds.

RAMSEM also works to help conserve Africa’s wildlife. The company is providing semen freezing services to ARK Biotech for preservation of African Buffalo, Rhinoceros and Lion genetics. With the opening of the lab, RAMSEM will expand its partnership with ARK Biotech to include semen sorting and invitro fertilization services.

-30-

Sexing Technologies® is the world leader and innovator and leader in livestock semen sex-sorting technology.

Attachment

Francisco Bobadilla
Sexing Technologies
936-870-3960
francisco.bobadilla@stgen.com

 

Results of the COLCORONA study published in The Lancet Respiratory Medicine

Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications MONTREAL, May 28, 2021 (GLOBE NEWSWIRE) — The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published in The Lancet Respiratory Medicine. The article, which is entitled Colchicine for community-treated patients […]

Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications

MONTREAL, May 28, 2021 (GLOBE NEWSWIRE) — The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published in The Lancet Respiratory Medicine. The article, which is entitled Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, concludes that, given the lack of oral therapies available to prevent COVID-19 complications among non-hospitalized patients and the observed benefit of colchicine in patients with a PCR-confirmed diagnosis of COVID-19, this anti-inflammatory drug could be considered as a treatment for those at risk of complications.

“Given the current pandemic, while awaiting collective immunity through vaccination around the world, the need for treatments to prevent COVID-19 complications among patients who contract the disease remains”, said Dr. Jean-Claude Tardif, Director of the MHI Research Centre, Professor at the Faculty of Medicine of the Université de Montréal and Principal Investigator of COLCORONA. “Our study showed that colchicine could be used to reduce the risk of complications for some patients with COVID-19.”

Colchicine is an inexpensive and readily available anti-inflammatory drug. Orally administered, it is currently prescribed to treat gout, Familial Mediterranean Fever and pericarditis. The COLCORONA study assessed colchicine’s potential to reduce the risk of COVID-19-related complications in outpatients over 40 years of age with at least one risk factor for disease progression.

The study’s primary efficacy endpoint was the composite of death or hospitalization in patients with COVID-19. Of the 4,488 patients enrolled, including those without a PCR-confirmed diagnosis, the primary endpoint occurred in 4.7% of patients in the colchicine group and 5.8% of those in the placebo group, a non-statistically significant result. For the 4,159 patients with a PCR-based diagnosis of COVID-19, the primary endpoint occurred in 4.6% of patients in the colchicine group and 6.0% of patients in the placebo group, a statistically significant result. Serious adverse events were reported in 4.9% of patients in the colchicine group and 6.3% of those in the placebo group. Notwithstanding these results, it is recommended that studies such as this one be replicated in non-hospitalized patients with a PCR-confirmed diagnosis of COVID-19. Full study results are available here: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00222-8/fulltext.

“The COLCORONA study expands on our knowledge of the role of oral, cheap and widely available repurposed drugs such as colchicine to treat people early on to prevent serious complications of COVID-19 and can help practitioners and their patients make informed treatment decisions,” said Yves Rosenberg, M.D., M.P.H., chief of the Atherothrombosis and Coronary Artery Disease Branch at the National Heart, Lung, and Blood Institute, part of the United States National Institutes of Health.

COLCORONA (NCT04322682) is a randomized, double-blinded, placebo-controlled, home-based clinical trial. It was conducted in Canada, the United States, Europe, South America, and South Africa. The study included 4,488 non-hospitalized patients over 40 years of age with COVID-19 at the time of inclusion, with at least one identified risk factor for COVID-19 complications (e.g., diabetes, hypertension, known respiratory disease, obesity). Patients were randomized to receive colchicine (0.5 mg twice daily for three days and once daily after) or placebo for 30 days.

The Montreal Health Innovation Coordinating Centre (MHICC) at the MHI coordinated COLCORONA, which was funded by the Quebec government, the National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH), Montreal philanthropist Sophie Desmarais, and the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard. Montreal-based CGI, Dacima and Pharmascience were also collaborators in the study.

About the Montreal Heart Institute 
Founded in 1954, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training, and prevention. It houses the largest cardiology research center in Canada, the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in Canada. The Institute is affiliated with the Université de Montréal and has more than 2,000 employees, including 245 doctors and more than 85 researchers. icm-mhi.org

About the Montreal Health Innovations Coordinating Center (MHICC) 
The Montreal Health Innovations Coordinating Center (MHICC) is a leading academic clinical research organization and an integral part of the Montreal Heart Institute (MHI). The MHICC possesses an established network of collaborators in over 4,500 clinical sites in more than 35 countries. It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing. mhicc.org

About Pharmascience
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. With its head office located in Montreal and its 1,500 employees, Pharmascience Inc. is a private pharmaceutical company with deep roots in Canada, and whose global reach spans across more than 60 countries. Ranked 47th among the top 100 Canadian investors in Research and Development (R&D), thanks to $49,5 million investment in 2018, Pharmascience Inc. is one of the largest manufacturer of generic drugs in the country. pharmascience.com

About CGI
Founded in 1976, CGI is one of the world’s largest information technology (IT) and management consulting firms. From hundreds of locations around the world, CGI offers a complete portfolio of services and solutions: strategic IT and management consulting services, systems integration services, intellectual property solutions as well as IT and business process management services in delegated mode. cgi.com/canada

About Dacima
Founded in 2006, Dacima Software Inc. is a leading innovator in Electronic Data Capture (EDC) software for clinical research. Dacima’s EDC software, Dacima Clinical Suite, is a fully feature EDC software application with integrated modules for patient randomization (IWRS), supply management, ePRO, eDiary, medical coding and eConsent. Dacima’s flexible and highly configurable EDC platforms allow for the design of all types of study designs including clinical trials, patient registries, observational studies and web surveys through an intuitive user-friendly web interface. dacimasoftware.com

About the COVID-19 Therapeutics Accelerator
The Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard with support from public and philanthropic donors to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments. Its partners are committed to equitable access, including making products available and affordable in low-resource settings. www.therapeuticsaccelerator.org

Relations médias :
Camille Turbide
Camille.turbide@gmail.com
+ 1 514 755-5354

International Big Data Expo Opens in Southwest China

GUIYANG, China, May 27, 2021 /PRNewswire/ — The 2021 China International Big Data Industry Expo (CIBDIE), the country’s leading big data expo, kicked off on May 26 in Guiyang, capital city of southwest China’s Guizhou Province, according to China International Big Data Industry Expo Organizing Committee. Founded in 2015 and officially upgraded to a national […]

GUIYANG, China, May 27, 2021 /PRNewswire/ — The 2021 China International Big Data Industry Expo (CIBDIE), the country’s leading big data expo, kicked off on May 26 in Guiyang, capital city of southwest China’s Guizhou Province, according to China International Big Data Industry Expo Organizing Committee.

International big data expo opens in southwest China.

Founded in 2015 and officially upgraded to a national expo in 2017, the big data expo has become an international and professional platform for the development of big data as well as an industrial bellwether.

The three-day event is jointly held by the local government as well as the country’s top economic planner, industrial and information watchdogs. With support from the China’s commerce ministry, the expo features domestic, global, industrial and business perspectives.

Under the theme “Embrace digital intelligence, Deliver new development”, the event will include conferences, exhibitions, new product launches, contests and other activities.

This year’s expo is scheduled both online and offline, seeking open cooperation and joint development of different stakeholders. The online expo offers services like online communication, online exhibition, business negotiation, online forum and guest promotion, presenting a variety of exhibition functions.

Guiyang City and Gui’an New District, as the core areas of the national big data (Guizhou) integrated pilot zone, have always been pioneers in big data development, posting leapfrogging progresses in industrial growth. More than 5,000 big data enterprises and 117 industrial giants were here by the end of 2020. The added value of digital economy reached 164.9 billion yuan (about 25.8 billion U.S. dollars), accounting for 38.2 percent of the regional GDP, and over half of the region’s real economy featured big data elements.

The specific activities of the expo are as follows:

Conferences: the opening and closing ceremonies, as well as 7 high-end dialogues and 13 professional forums.

Exhibitions: Online and offline exhibitions to display new technologies, new products, new schemes and new applications in the field of big data. A section on big data’s role in rural revitalization is also established.

New launches: Releases of the expo’s leading science and technology achievement award, research on methods and paths of data factor market, global prediction system of COVID-19 and the dictionary of big data encyclopedia, etc.

Competitions: The 2nd industrial APP integration innovation competition and the 6th Guiyang big data and network security elite confrontation exercise.

Activities: a series of activities such as meetings and exchanges, talent introductions, night talks, salons and dialogues, promotions and contract-signing, strategic cooperation, organized visits, etc.

Image Attachments Links:

Link: http://asianetnews.net/view-attachment?attach-id=392265
Caption: International big data expo opens in southwest China.

Photo – https://mma.prnewswire.com/media/1519935/2021_CIBDIE.jpg

Taconic Biosciences Launches TruIMPORT™ Importation Solution

Rodent Models Originating in China Can Be Imported Into Virtually Any Academic Vivarium Without Quarantine RENSSELAER, N.Y., May 27, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces a significant enhancement to the Taconic-Cyagen Model Generation Alliance allowing seamless importation of new genetically engineered models originating in […]

Rodent Models Originating in China Can Be Imported Into Virtually Any Academic Vivarium Without Quarantine

RENSSELAER, N.Y., May 27, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces a significant enhancement to the Taconic-Cyagen Model Generation Alliance allowing seamless importation of new genetically engineered models originating in China under the TruIMPORT™ umbrella.

Researchers at non-profit institutions play a critical role in drug discovery; however, outsourcing animal model generation can be cost prohibitive or a logistical challenge. Hurdles in accessing animal model resources can impede important research. Potential solutions to this problem have traditionally come with trade-offs. Depending on the country of origin, cost effective options can require a lengthy quarantine of the animals or additional breeding to ensure animals meet the required health standards for entry into the institution’s animal facility. These additional steps can cost the researcher both time and money.

Originally launched in 2018, the Taconic-Cyagen Model Generation Alliance (the Alliance) for academic and non-profit researchers leverages the talents of two industry-leading companies to create a solution uniquely tailored for non-profit research institutions. Taconic Biosciences has over 65 years of rodent model experience and Cyagen Biosciences is a China-based leader in model generation efficiency and a competitive cost structure. Since its inception, the Alliance has become a recognized leader in providing model generation services to academics and non-profit researchers. TruIMPORT™ represents an important evolution in this service offering. It allows animal models from China to be imported into United States and European animal facilities while complying with existing vivarium requirements. Providing a set of choices, TruIMPORT™ allows customers to access efficient model generation with several pricing options depending on desired delivery timeline, health standard, and cohort size.

“Our main goal is to solve problems for our customers,” shared Dr. John Couse, vice president of scientific services for Taconic. “While the Alliance has provided efficient model generation for years, importation concerns were a barrier for many customers. By creating multiple options under the TruIMPORT™ umbrella, customers can now import rodent models from China without quarantine regardless of the requirements of their vivarium.”

The TruIMPORT™ portfolio consists of three importation options: RapidRELAY™, RapidCHECK™, and RapidEXPANSION™. Customers can compare product specifications here to determine which represents the right combination of timeline, health standards, and deliverables to meet their needs.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model generation and colony management services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

About Cyagen Biosciences, Inc.

Cyagen Biosciences is a leading provider of comprehensive genetically engineered rodent model services. Cyagen utilizes a highly efficient process, including its proprietary AI technology, to design and deliver novel genetically engineered models with precision and competitive pricing. The Cyagen Transgenic Animal Center (CTAC) in China is a state-of-the-art, specific-pathogen free (SPF) barrier facility, which is both AAALAC accredited and OLAW assured. Cyagen has additional locations in the United States, Japan, and China. Since Cyagen’s founding in 2005, we have delivered over 78,400 animal models to researchers worldwide and have been cited in over 4,700 publications.

Media Contact:

Kelly Owen Grover

Director of Marketing Communications

518-478-6095

kelly.grover@taconic.com

GMAC Welcomes Top Latin American Business School as Its Newest Member

EGADE Business School brings diversity and prestige to the Council RESTON, Va., May 27, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council™ (GMAC™) today announced that EGADE Business School at Tecnológico de Monterrey has become the Council’s latest member. Located in Mexico, the EGADE Business School is selected for its world-class programs and international recognition in and beyond […]

EGADE Business School brings diversity and prestige to the Council

RESTON, Va., May 27, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council™ (GMAC™) today announced that EGADE Business School at Tecnológico de Monterrey has become the Council’s latest member. Located in Mexico, the EGADE Business School is selected for its world-class programs and international recognition in and beyond Latin America, adding great representation of the region to the global association that constitutes 229 top business schools around the world.

“EGADE Business School at Tecnológico de Monterrey has built a globally recognized reputation as the leading Latin American business education institution, committed to empowering entrepreneurial leaders who create shared value and transform society,” said Dr. Osmar Zavaleta, interim dean of EGADE Business School. “EGADE is committed to the exchange of ideas and best practices with our global peers and GMAC membership provides a valuable platform for enhancing that exchange other GMAC member schools”.

“The pandemic has taught us to be innovative and adaptive in a disruptive environment of an interconnected world,” said Sangeet Chowfla, president and CEO of GMAC. “We value the global vision and holistic approach that EGADE Business School brings and look forward to their contributions to the advancement of graduate management education.”

EGADE Business Schools is among a select group of institutions internationally to hold the “triple-crown” of excellence from the three leading global accreditation systems for business education quality assessment and continuous improvement: Association to Advance Collegiate Schools of Business (AACSB), Association of MBAs (AMBA), and EFMD Quality Improvement System (EQUIS). For the fourth consecutive year in 2021, EGADE Business School topped the Quacquarelli Symonds (QS) ranking in Mexico and Latin America for its Full-Time MBA in Innovation & Entrepreneurship and Master in Finance programs and appears for the first time as the regional leader for its recently introduced Masters in Management.

To be considered for membership in GMAC, a school must maintain a selective admissions process; offer a master’s program in business administration, management subjects or equivalent; and demonstrate support of GMAC’s mission through the use of its products and services.

About GMAC

The Graduate Management Admission Council™ (GMAC™) is a mission-driven association of leading graduate business schools worldwide. Founded in 1953, GMAC creates solutions and experiences that enable business schools and candidates to better discover, evaluate, and connect with each other.

GMAC™ provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as tools, resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

GMAC™ also owns and administers the NMAT by GMAC™ (NMAT™) exam and the Executive Assessment (EA). More than 7 million candidates on their business master’s or MBA journey visited GMAC’s mba.com last year to explore business school options, prepare and register for exams, and get advice on the admissions process. BusinessBecause and The MBA Tour are subsidiaries of GMAC™, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202-390-4180 (mobile)
thsu@gmac.com